nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCG2—hematologic cancer	0.15	0.54	CbGaD
Vismodegib—ALB—hematologic cancer	0.0656	0.235	CbGaD
Vismodegib—ABCB1—hematologic cancer	0.0626	0.225	CbGaD
Vismodegib—ABCG2—Clofarabine—hematologic cancer	0.0282	0.06	CbGbCtD
Vismodegib—ORM1—Imatinib—hematologic cancer	0.0208	0.0442	CbGbCtD
Vismodegib—ABCG2—Daunorubicin—hematologic cancer	0.0166	0.0352	CbGbCtD
Vismodegib—ABCG2—Teniposide—hematologic cancer	0.0144	0.0306	CbGbCtD
Vismodegib—ABCG2—Cladribine—hematologic cancer	0.0138	0.0293	CbGbCtD
Vismodegib—ABCG2—Imatinib—hematologic cancer	0.0127	0.027	CbGbCtD
Vismodegib—ABCG2—Nilotinib—hematologic cancer	0.0115	0.0245	CbGbCtD
Vismodegib—CYP2C9—Bexarotene—hematologic cancer	0.0105	0.0223	CbGbCtD
Vismodegib—ABCG2—Dasatinib—hematologic cancer	0.0102	0.0217	CbGbCtD
Vismodegib—ABCB1—Lenalidomide—hematologic cancer	0.0102	0.0216	CbGbCtD
Vismodegib—ABCG2—Mitoxantrone—hematologic cancer	0.0101	0.0214	CbGbCtD
Vismodegib—CYP2C8—Bortezomib—hematologic cancer	0.00922	0.0196	CbGbCtD
Vismodegib—ALB—Imatinib—hematologic cancer	0.00874	0.0186	CbGbCtD
Vismodegib—CYP2C9—Idarubicin—hematologic cancer	0.00869	0.0185	CbGbCtD
Vismodegib—ABCG2—Irinotecan—hematologic cancer	0.00792	0.0168	CbGbCtD
Vismodegib—CYP2C19—Bortezomib—hematologic cancer	0.00774	0.0164	CbGbCtD
Vismodegib—CYP2C8—Ifosfamide—hematologic cancer	0.00707	0.015	CbGbCtD
Vismodegib—ABCG2—Vincristine—hematologic cancer	0.00692	0.0147	CbGbCtD
Vismodegib—CYP2C19—Thalidomide—hematologic cancer	0.00674	0.0143	CbGbCtD
Vismodegib—ABCG2—Cisplatin—hematologic cancer	0.00646	0.0137	CbGbCtD
Vismodegib—CYP2C9—Bortezomib—hematologic cancer	0.00643	0.0137	CbGbCtD
Vismodegib—CYP2C19—Teniposide—hematologic cancer	0.00643	0.0137	CbGbCtD
Vismodegib—ABCG2—Etoposide—hematologic cancer	0.00634	0.0135	CbGbCtD
Vismodegib—CYP2C8—Nilotinib—hematologic cancer	0.00614	0.0131	CbGbCtD
Vismodegib—CYP3A4—Bexarotene—hematologic cancer	0.0061	0.013	CbGbCtD
Vismodegib—ABCB1—Daunorubicin—hematologic cancer	0.00597	0.0127	CbGbCtD
Vismodegib—CYP2C19—Ifosfamide—hematologic cancer	0.00593	0.0126	CbGbCtD
Vismodegib—ABCB1—Alitretinoin—hematologic cancer	0.00585	0.0124	CbGbCtD
Vismodegib—ALB—Prednisone—hematologic cancer	0.00576	0.0122	CbGbCtD
Vismodegib—CYP3A4—Busulfan—hematologic cancer	0.00567	0.0121	CbGbCtD
Vismodegib—CYP3A4—Lomustine—hematologic cancer	0.00567	0.0121	CbGbCtD
Vismodegib—CYP2C19—Imatinib—hematologic cancer	0.00567	0.012	CbGbCtD
Vismodegib—CYP2C9—Thalidomide—hematologic cancer	0.0056	0.0119	CbGbCtD
Vismodegib—ALB—Irinotecan—hematologic cancer	0.00546	0.0116	CbGbCtD
Vismodegib—CYP2C9—Teniposide—hematologic cancer	0.00534	0.0114	CbGbCtD
Vismodegib—ABCG2—Dexamethasone—hematologic cancer	0.00522	0.0111	CbGbCtD
Vismodegib—CYP3A4—Thiotepa—hematologic cancer	0.00506	0.0107	CbGbCtD
Vismodegib—CYP2C9—Ifosfamide—hematologic cancer	0.00493	0.0105	CbGbCtD
Vismodegib—CYP2C9—Imatinib—hematologic cancer	0.00471	0.01	CbGbCtD
Vismodegib—ABCB1—Imatinib—hematologic cancer	0.00457	0.00972	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—hematologic cancer	0.00433	0.0092	CbGbCtD
Vismodegib—CYP2C9—Nilotinib—hematologic cancer	0.00428	0.0091	CbGbCtD
Vismodegib—ABCG2—Methotrexate—hematologic cancer	0.00419	0.00891	CbGbCtD
Vismodegib—ABCB1—Nilotinib—hematologic cancer	0.00416	0.00883	CbGbCtD
Vismodegib—ABCB1—Vinorelbine—hematologic cancer	0.00412	0.00876	CbGbCtD
Vismodegib—CYP3A4—Methoxsalen—hematologic cancer	0.00393	0.00836	CbGbCtD
Vismodegib—CYP3A4—Bortezomib—hematologic cancer	0.00374	0.00795	CbGbCtD
Vismodegib—CYP2C19—Prednisone—hematologic cancer	0.00373	0.00794	CbGbCtD
Vismodegib—ABCB1—Dasatinib—hematologic cancer	0.00367	0.00781	CbGbCtD
Vismodegib—ABCB1—Mitoxantrone—hematologic cancer	0.00363	0.00771	CbGbCtD
Vismodegib—CYP3A4—Daunorubicin—hematologic cancer	0.00358	0.0076	CbGbCtD
Vismodegib—CYP2C8—Etoposide—hematologic cancer	0.00338	0.00719	CbGbCtD
Vismodegib—ABCB1—Betamethasone—hematologic cancer	0.00323	0.00687	CbGbCtD
Vismodegib—ABCB1—Gemcitabine—hematologic cancer	0.0032	0.00681	CbGbCtD
Vismodegib—ABCB1—Prednisolone—hematologic cancer	0.00319	0.00678	CbGbCtD
Vismodegib—CYP3A4—Cytarabine—hematologic cancer	0.00316	0.00671	CbGbCtD
Vismodegib—CYP3A4—Teniposide—hematologic cancer	0.00311	0.00661	CbGbCtD
Vismodegib—ABCB1—Prednisone—hematologic cancer	0.00301	0.00641	CbGbCtD
Vismodegib—ALB—Methotrexate—hematologic cancer	0.00289	0.00614	CbGbCtD
Vismodegib—CYP3A4—Ifosfamide—hematologic cancer	0.00287	0.0061	CbGbCtD
Vismodegib—ABCB1—Irinotecan—hematologic cancer	0.00286	0.00607	CbGbCtD
Vismodegib—CYP2C8—Dexamethasone—hematologic cancer	0.00278	0.00591	CbGbCtD
Vismodegib—CYP3A4—Imatinib—hematologic cancer	0.00274	0.00582	CbGbCtD
Vismodegib—CYP3A4—Ruxolitinib—hematologic cancer	0.00258	0.00548	CbGbCtD
Vismodegib—ABCB1—Vinblastine—hematologic cancer	0.00254	0.0054	CbGbCtD
Vismodegib—ABCB1—Vincristine—hematologic cancer	0.0025	0.00531	CbGbCtD
Vismodegib—CYP3A4—Nilotinib—hematologic cancer	0.00249	0.00529	CbGbCtD
Vismodegib—CYP3A4—Vinorelbine—hematologic cancer	0.00247	0.00525	CbGbCtD
Vismodegib—CYP2C9—Cisplatin—hematologic cancer	0.0024	0.0051	CbGbCtD
Vismodegib—CYP2C19—Dexamethasone—hematologic cancer	0.00233	0.00496	CbGbCtD
Vismodegib—ABCB1—Cisplatin—hematologic cancer	0.00233	0.00495	CbGbCtD
Vismodegib—ABCB1—Etoposide—hematologic cancer	0.00229	0.00486	CbGbCtD
Vismodegib—CYP3A4—Triamcinolone—hematologic cancer	0.00226	0.0048	CbGbCtD
Vismodegib—CYP3A4—Dasatinib—hematologic cancer	0.0022	0.00468	CbGbCtD
Vismodegib—CYP3A4—Mitoxantrone—hematologic cancer	0.00217	0.00462	CbGbCtD
Vismodegib—CYP2C9—Dexamethasone—hematologic cancer	0.00194	0.00412	CbGbCtD
Vismodegib—CYP3A4—Betamethasone—hematologic cancer	0.00194	0.00412	CbGbCtD
Vismodegib—SHH—bone marrow—hematologic cancer	0.00192	0.112	CbGeAlD
Vismodegib—CYP3A4—Prednisolone—hematologic cancer	0.00191	0.00406	CbGbCtD
Vismodegib—ABCB1—Dexamethasone—hematologic cancer	0.00188	0.004	CbGbCtD
Vismodegib—CYP3A4—Prednisone—hematologic cancer	0.00181	0.00384	CbGbCtD
Vismodegib—SHH—lung—hematologic cancer	0.00174	0.101	CbGeAlD
Vismodegib—CYP3A4—Irinotecan—hematologic cancer	0.00171	0.00364	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—hematologic cancer	0.00156	0.00332	CbGbCtD
Vismodegib—CYP3A4—Vinblastine—hematologic cancer	0.00152	0.00323	CbGbCtD
Vismodegib—ABCB1—Methotrexate—hematologic cancer	0.00151	0.00321	CbGbCtD
Vismodegib—CYP3A4—Vincristine—hematologic cancer	0.0015	0.00318	CbGbCtD
Vismodegib—CYP3A4—Etoposide—hematologic cancer	0.00137	0.00291	CbGbCtD
Vismodegib—SMO—lung—hematologic cancer	0.00121	0.0707	CbGeAlD
Vismodegib—SMO—testis—hematologic cancer	0.00115	0.0667	CbGeAlD
Vismodegib—CYP3A4—Dexamethasone—hematologic cancer	0.00113	0.0024	CbGbCtD
Vismodegib—Etoricoxib—MAPK14—hematologic cancer	0.001	0.212	CrCbGaD
Vismodegib—CYP3A4—Doxorubicin—hematologic cancer	0.000935	0.00199	CbGbCtD
Vismodegib—ORM1—hematopoietic system—hematologic cancer	0.000914	0.0532	CbGeAlD
Vismodegib—SMO—lymph node—hematologic cancer	0.000831	0.0484	CbGeAlD
Vismodegib—Sorafenib—FLT3—hematologic cancer	0.000737	0.156	CrCbGaD
Vismodegib—CYP2C19—hematopoietic system—hematologic cancer	0.000645	0.0376	CbGeAlD
Vismodegib—ORM1—blood—hematologic cancer	0.000605	0.0353	CbGeAlD
Vismodegib—ORM1—bone marrow—hematologic cancer	0.000586	0.0341	CbGeAlD
Vismodegib—CYP2C8—hematopoietic system—hematologic cancer	0.000563	0.0328	CbGeAlD
Vismodegib—ORM1—lung—hematologic cancer	0.000531	0.0309	CbGeAlD
Vismodegib—CYP2C9—hematopoietic system—hematologic cancer	0.0005	0.0291	CbGeAlD
Vismodegib—Sorafenib—RET—hematologic cancer	0.000475	0.1	CrCbGaD
Vismodegib—ALB—testis—hematologic cancer	0.000439	0.0256	CbGeAlD
Vismodegib—CYP2C19—blood—hematologic cancer	0.000427	0.0249	CbGeAlD
Vismodegib—CYP3A4—hematopoietic system—hematologic cancer	0.000381	0.0222	CbGeAlD
Vismodegib—Sorafenib—CSF1R—hematologic cancer	0.000377	0.0797	CrCbGaD
Vismodegib—CYP2C8—blood—hematologic cancer	0.000373	0.0217	CbGeAlD
Vismodegib—ORM1—lymph node—hematologic cancer	0.000363	0.0211	CbGeAlD
Vismodegib—ABCG2—blood—hematologic cancer	0.000363	0.0211	CbGeAlD
Vismodegib—ABCG2—bone marrow—hematologic cancer	0.000351	0.0204	CbGeAlD
Vismodegib—CYP2C9—blood—hematologic cancer	0.000331	0.0193	CbGeAlD
Vismodegib—Sorafenib—PDGFRB—hematologic cancer	0.000329	0.0695	CrCbGaD
Vismodegib—Sorafenib—PDGFRA—hematologic cancer	0.000321	0.0677	CrCbGaD
Vismodegib—ALB—lymph node—hematologic cancer	0.000318	0.0185	CbGeAlD
Vismodegib—ABCG2—lung—hematologic cancer	0.000318	0.0185	CbGeAlD
Vismodegib—CYP2C8—testis—hematologic cancer	0.000309	0.018	CbGeAlD
Vismodegib—ABCG2—testis—hematologic cancer	0.0003	0.0175	CbGeAlD
Vismodegib—Sorafenib—BRAF—hematologic cancer	0.000294	0.062	CrCbGaD
Vismodegib—Sulfasalazine—ALOX5—hematologic cancer	0.00028	0.0591	CrCbGaD
Vismodegib—ABCB1—hematopoietic system—hematologic cancer	0.00027	0.0157	CbGeAlD
Vismodegib—CYP3A4—blood—hematologic cancer	0.000253	0.0147	CbGeAlD
Vismodegib—Sorafenib—KIT—hematologic cancer	0.000236	0.0497	CrCbGaD
Vismodegib—Sorafenib—UGT1A1—hematologic cancer	0.000232	0.049	CrCbGaD
Vismodegib—ABCG2—lymph node—hematologic cancer	0.000217	0.0127	CbGeAlD
Vismodegib—ABCB1—gonad—hematologic cancer	0.000205	0.012	CbGeAlD
Vismodegib—ABCB1—blood—hematologic cancer	0.000179	0.0104	CbGeAlD
Vismodegib—ABCB1—bone marrow—hematologic cancer	0.000173	0.0101	CbGeAlD
Vismodegib—ABCB1—lung—hematologic cancer	0.000157	0.00913	CbGeAlD
Vismodegib—ABCB1—testis—hematologic cancer	0.000148	0.00862	CbGeAlD
Vismodegib—Sulfasalazine—ABCG2—hematologic cancer	0.000138	0.0292	CrCbGaD
Vismodegib—Sorafenib—ABCG2—hematologic cancer	0.00013	0.0275	CrCbGaD
Vismodegib—Tolvaptan—ABCB1—hematologic cancer	0.000129	0.0272	CrCbGaD
Vismodegib—ABCB1—lymph node—hematologic cancer	0.000107	0.00625	CbGeAlD
Vismodegib—Asthenia—Thalidomide—hematologic cancer	5.59e-05	0.000406	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—hematologic cancer	5.57e-05	0.000405	CcSEcCtD
Vismodegib—Nausea—Lenalidomide—hematologic cancer	5.57e-05	0.000405	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—hematologic cancer	5.55e-05	0.000403	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—hematologic cancer	5.51e-05	0.0004	CcSEcCtD
Vismodegib—Pruritus—Thalidomide—hematologic cancer	5.51e-05	0.0004	CcSEcCtD
Vismodegib—Diarrhoea—Thiotepa—hematologic cancer	5.51e-05	0.0004	CcSEcCtD
Vismodegib—Abdominal pain—Mitoxantrone—hematologic cancer	5.49e-05	0.000399	CcSEcCtD
Vismodegib—Abdominal pain—Irinotecan—hematologic cancer	5.49e-05	0.000399	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—hematologic cancer	5.49e-05	0.000399	CcSEcCtD
Vismodegib—Nausea—Hydroxyurea—hematologic cancer	5.49e-05	0.000399	CcSEcCtD
Vismodegib—Vomiting—Bortezomib—hematologic cancer	5.49e-05	0.000398	CcSEcCtD
Vismodegib—Decreased appetite—Cisplatin—hematologic cancer	5.49e-05	0.000398	CcSEcCtD
Vismodegib—Myalgia—Triamcinolone—hematologic cancer	5.47e-05	0.000397	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Cisplatin—hematologic cancer	5.45e-05	0.000396	CcSEcCtD
Vismodegib—Vomiting—Bleomycin—hematologic cancer	5.45e-05	0.000395	CcSEcCtD
Vismodegib—Rash—Bortezomib—hematologic cancer	5.44e-05	0.000395	CcSEcCtD
Vismodegib—Dermatitis—Bortezomib—hematologic cancer	5.44e-05	0.000395	CcSEcCtD
Vismodegib—Sorafenib—ABCB1—hematologic cancer	5.43e-05	0.0115	CrCbGaD
Vismodegib—Rash—Bleomycin—hematologic cancer	5.4e-05	0.000392	CcSEcCtD
Vismodegib—Pain—Cisplatin—hematologic cancer	5.4e-05	0.000392	CcSEcCtD
Vismodegib—Dermatitis—Bleomycin—hematologic cancer	5.4e-05	0.000392	CcSEcCtD
Vismodegib—Asthenia—Carmustine—hematologic cancer	5.36e-05	0.00039	CcSEcCtD
Vismodegib—Vomiting—Vinorelbine—hematologic cancer	5.36e-05	0.000389	CcSEcCtD
Vismodegib—Diarrhoea—Thalidomide—hematologic cancer	5.33e-05	0.000387	CcSEcCtD
Vismodegib—Asthenia—Alitretinoin—hematologic cancer	5.31e-05	0.000386	CcSEcCtD
Vismodegib—Rash—Vinorelbine—hematologic cancer	5.31e-05	0.000386	CcSEcCtD
Vismodegib—Dermatitis—Vinorelbine—hematologic cancer	5.31e-05	0.000385	CcSEcCtD
Vismodegib—Asthenia—Ifosfamide—hematologic cancer	5.25e-05	0.000381	CcSEcCtD
Vismodegib—Pruritus—Alitretinoin—hematologic cancer	5.24e-05	0.000381	CcSEcCtD
Vismodegib—Pruritus—Ifosfamide—hematologic cancer	5.18e-05	0.000376	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—hematologic cancer	5.16e-05	0.000374	CcSEcCtD
Vismodegib—Alopecia—Prednisone—hematologic cancer	5.15e-05	0.000374	CcSEcCtD
Vismodegib—Nausea—Bortezomib—hematologic cancer	5.13e-05	0.000372	CcSEcCtD
Vismodegib—Asthenia—Vincristine—hematologic cancer	5.12e-05	0.000372	CcSEcCtD
Vismodegib—Vomiting—Thiotepa—hematologic cancer	5.12e-05	0.000372	CcSEcCtD
Vismodegib—Diarrhoea—Carmustine—hematologic cancer	5.12e-05	0.000371	CcSEcCtD
Vismodegib—Nausea—Bleomycin—hematologic cancer	5.09e-05	0.000369	CcSEcCtD
Vismodegib—Malnutrition—Prednisone—hematologic cancer	5.08e-05	0.000369	CcSEcCtD
Vismodegib—Rash—Thiotepa—hematologic cancer	5.07e-05	0.000368	CcSEcCtD
Vismodegib—Dermatitis—Thiotepa—hematologic cancer	5.07e-05	0.000368	CcSEcCtD
Vismodegib—Diarrhoea—Alitretinoin—hematologic cancer	5.07e-05	0.000368	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—hematologic cancer	5.03e-05	0.000365	CcSEcCtD
Vismodegib—Diarrhoea—Ifosfamide—hematologic cancer	5.01e-05	0.000364	CcSEcCtD
Vismodegib—Nausea—Vinorelbine—hematologic cancer	5.01e-05	0.000363	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Etoposide—hematologic cancer	4.99e-05	0.000362	CcSEcCtD
Vismodegib—Asthenia—Mitoxantrone—hematologic cancer	4.99e-05	0.000362	CcSEcCtD
Vismodegib—Asthenia—Irinotecan—hematologic cancer	4.99e-05	0.000362	CcSEcCtD
Vismodegib—Fatigue—Etoposide—hematologic cancer	4.98e-05	0.000362	CcSEcCtD
Vismodegib—Myalgia—Dexamethasone—hematologic cancer	4.96e-05	0.00036	CcSEcCtD
Vismodegib—Myalgia—Betamethasone—hematologic cancer	4.96e-05	0.00036	CcSEcCtD
Vismodegib—Vomiting—Thalidomide—hematologic cancer	4.95e-05	0.000359	CcSEcCtD
Vismodegib—Pain—Etoposide—hematologic cancer	4.94e-05	0.000359	CcSEcCtD
Vismodegib—Constipation—Etoposide—hematologic cancer	4.94e-05	0.000359	CcSEcCtD
Vismodegib—Rash—Thalidomide—hematologic cancer	4.91e-05	0.000356	CcSEcCtD
Vismodegib—Dermatitis—Thalidomide—hematologic cancer	4.9e-05	0.000356	CcSEcCtD
Vismodegib—Diarrhoea—Vincristine—hematologic cancer	4.88e-05	0.000355	CcSEcCtD
Vismodegib—Pain—Prednisolone—hematologic cancer	4.88e-05	0.000354	CcSEcCtD
Vismodegib—Asthenia—Gemcitabine—hematologic cancer	4.86e-05	0.000353	CcSEcCtD
Vismodegib—Pruritus—Gemcitabine—hematologic cancer	4.79e-05	0.000348	CcSEcCtD
Vismodegib—Nausea—Thiotepa—hematologic cancer	4.78e-05	0.000347	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	4.78e-05	0.000347	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—hematologic cancer	4.77e-05	0.000346	CcSEcCtD
Vismodegib—Diarrhoea—Mitoxantrone—hematologic cancer	4.76e-05	0.000345	CcSEcCtD
Vismodegib—Diarrhoea—Irinotecan—hematologic cancer	4.76e-05	0.000345	CcSEcCtD
Vismodegib—Vomiting—Carmustine—hematologic cancer	4.75e-05	0.000345	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—hematologic cancer	4.73e-05	0.000343	CcSEcCtD
Vismodegib—Rash—Carmustine—hematologic cancer	4.71e-05	0.000342	CcSEcCtD
Vismodegib—Dermatitis—Carmustine—hematologic cancer	4.71e-05	0.000342	CcSEcCtD
Vismodegib—Vomiting—Alitretinoin—hematologic cancer	4.71e-05	0.000342	CcSEcCtD
Vismodegib—Rash—Alitretinoin—hematologic cancer	4.67e-05	0.000339	CcSEcCtD
Vismodegib—Nervous system disorder—Dexamethasone—hematologic cancer	4.67e-05	0.000339	CcSEcCtD
Vismodegib—Nervous system disorder—Betamethasone—hematologic cancer	4.67e-05	0.000339	CcSEcCtD
Vismodegib—Dermatitis—Alitretinoin—hematologic cancer	4.67e-05	0.000339	CcSEcCtD
Vismodegib—Vomiting—Ifosfamide—hematologic cancer	4.65e-05	0.000338	CcSEcCtD
Vismodegib—Diarrhoea—Gemcitabine—hematologic cancer	4.63e-05	0.000336	CcSEcCtD
Vismodegib—Nausea—Thalidomide—hematologic cancer	4.62e-05	0.000336	CcSEcCtD
Vismodegib—Dyspepsia—Triamcinolone—hematologic cancer	4.62e-05	0.000335	CcSEcCtD
Vismodegib—Rash—Ifosfamide—hematologic cancer	4.62e-05	0.000335	CcSEcCtD
Vismodegib—Dermatitis—Ifosfamide—hematologic cancer	4.61e-05	0.000335	CcSEcCtD
Vismodegib—Abdominal pain—Etoposide—hematologic cancer	4.57e-05	0.000332	CcSEcCtD
Vismodegib—Vomiting—Vincristine—hematologic cancer	4.54e-05	0.00033	CcSEcCtD
Vismodegib—Asthenia—Cisplatin—hematologic cancer	4.53e-05	0.000329	CcSEcCtD
Vismodegib—Fatigue—Triamcinolone—hematologic cancer	4.52e-05	0.000328	CcSEcCtD
Vismodegib—Rash—Vincristine—hematologic cancer	4.5e-05	0.000327	CcSEcCtD
Vismodegib—Dermatitis—Vincristine—hematologic cancer	4.5e-05	0.000326	CcSEcCtD
Vismodegib—Pain—Triamcinolone—hematologic cancer	4.48e-05	0.000326	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—hematologic cancer	4.48e-05	0.000325	CcSEcCtD
Vismodegib—Nausea—Carmustine—hematologic cancer	4.44e-05	0.000322	CcSEcCtD
Vismodegib—Vomiting—Mitoxantrone—hematologic cancer	4.42e-05	0.000321	CcSEcCtD
Vismodegib—Vomiting—Irinotecan—hematologic cancer	4.42e-05	0.000321	CcSEcCtD
Vismodegib—Nausea—Alitretinoin—hematologic cancer	4.4e-05	0.000319	CcSEcCtD
Vismodegib—Rash—Irinotecan—hematologic cancer	4.38e-05	0.000318	CcSEcCtD
Vismodegib—Rash—Mitoxantrone—hematologic cancer	4.38e-05	0.000318	CcSEcCtD
Vismodegib—Dermatitis—Irinotecan—hematologic cancer	4.38e-05	0.000318	CcSEcCtD
Vismodegib—Dermatitis—Mitoxantrone—hematologic cancer	4.38e-05	0.000318	CcSEcCtD
Vismodegib—Nausea—Ifosfamide—hematologic cancer	4.35e-05	0.000316	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.33e-05	0.000315	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.33e-05	0.000315	CcSEcCtD
Vismodegib—Arthralgia—Prednisone—hematologic cancer	4.32e-05	0.000314	CcSEcCtD
Vismodegib—Myalgia—Prednisone—hematologic cancer	4.32e-05	0.000314	CcSEcCtD
Vismodegib—Diarrhoea—Cisplatin—hematologic cancer	4.32e-05	0.000314	CcSEcCtD
Vismodegib—Alopecia—Methotrexate—hematologic cancer	4.31e-05	0.000313	CcSEcCtD
Vismodegib—Vomiting—Gemcitabine—hematologic cancer	4.3e-05	0.000313	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.29e-05	0.000312	CcSEcCtD
Vismodegib—Rash—Gemcitabine—hematologic cancer	4.27e-05	0.00031	CcSEcCtD
Vismodegib—Dermatitis—Gemcitabine—hematologic cancer	4.26e-05	0.00031	CcSEcCtD
Vismodegib—Malnutrition—Methotrexate—hematologic cancer	4.24e-05	0.000308	CcSEcCtD
Vismodegib—Nausea—Vincristine—hematologic cancer	4.24e-05	0.000308	CcSEcCtD
Vismodegib—Dyspepsia—Dexamethasone—hematologic cancer	4.19e-05	0.000304	CcSEcCtD
Vismodegib—Dyspepsia—Betamethasone—hematologic cancer	4.19e-05	0.000304	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—hematologic cancer	4.16e-05	0.000302	CcSEcCtD
Vismodegib—Asthenia—Etoposide—hematologic cancer	4.15e-05	0.000301	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—hematologic cancer	4.15e-05	0.000301	CcSEcCtD
Vismodegib—Decreased appetite—Dexamethasone—hematologic cancer	4.14e-05	0.0003	CcSEcCtD
Vismodegib—Decreased appetite—Betamethasone—hematologic cancer	4.14e-05	0.0003	CcSEcCtD
Vismodegib—Nausea—Irinotecan—hematologic cancer	4.13e-05	0.0003	CcSEcCtD
Vismodegib—Nausea—Mitoxantrone—hematologic cancer	4.13e-05	0.0003	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.11e-05	0.000298	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.11e-05	0.000298	CcSEcCtD
Vismodegib—Back pain—Methotrexate—hematologic cancer	4.1e-05	0.000298	CcSEcCtD
Vismodegib—Fatigue—Betamethasone—hematologic cancer	4.1e-05	0.000298	CcSEcCtD
Vismodegib—Fatigue—Dexamethasone—hematologic cancer	4.1e-05	0.000298	CcSEcCtD
Vismodegib—Pruritus—Etoposide—hematologic cancer	4.09e-05	0.000297	CcSEcCtD
Vismodegib—Pain—Betamethasone—hematologic cancer	4.07e-05	0.000295	CcSEcCtD
Vismodegib—Pain—Dexamethasone—hematologic cancer	4.07e-05	0.000295	CcSEcCtD
Vismodegib—Nervous system disorder—Prednisone—hematologic cancer	4.06e-05	0.000295	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—hematologic cancer	4.03e-05	0.000293	CcSEcCtD
Vismodegib—Skin disorder—Prednisone—hematologic cancer	4.02e-05	0.000292	CcSEcCtD
Vismodegib—Nausea—Gemcitabine—hematologic cancer	4.02e-05	0.000292	CcSEcCtD
Vismodegib—Vomiting—Cisplatin—hematologic cancer	4.01e-05	0.000291	CcSEcCtD
Vismodegib—Rash—Cisplatin—hematologic cancer	3.98e-05	0.000289	CcSEcCtD
Vismodegib—Dermatitis—Cisplatin—hematologic cancer	3.98e-05	0.000289	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—hematologic cancer	3.97e-05	0.000288	CcSEcCtD
Vismodegib—Diarrhoea—Etoposide—hematologic cancer	3.96e-05	0.000287	CcSEcCtD
Vismodegib—Gastrointestinal pain—Betamethasone—hematologic cancer	3.89e-05	0.000283	CcSEcCtD
Vismodegib—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.89e-05	0.000283	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—hematologic cancer	3.89e-05	0.000282	CcSEcCtD
Vismodegib—Back pain—Epirubicin—hematologic cancer	3.84e-05	0.000279	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—hematologic cancer	3.82e-05	0.000277	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.78e-05	0.000274	CcSEcCtD
Vismodegib—Asthenia—Triamcinolone—hematologic cancer	3.76e-05	0.000273	CcSEcCtD
Vismodegib—Abdominal pain—Dexamethasone—hematologic cancer	3.76e-05	0.000273	CcSEcCtD
Vismodegib—Abdominal pain—Betamethasone—hematologic cancer	3.76e-05	0.000273	CcSEcCtD
Vismodegib—Nausea—Cisplatin—hematologic cancer	3.75e-05	0.000272	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—hematologic cancer	3.73e-05	0.000271	CcSEcCtD
Vismodegib—Pruritus—Triamcinolone—hematologic cancer	3.71e-05	0.000269	CcSEcCtD
Vismodegib—Vomiting—Etoposide—hematologic cancer	3.68e-05	0.000267	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—hematologic cancer	3.67e-05	0.000267	CcSEcCtD
Vismodegib—Dyspepsia—Prednisone—hematologic cancer	3.65e-05	0.000265	CcSEcCtD
Vismodegib—Rash—Etoposide—hematologic cancer	3.65e-05	0.000265	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—hematologic cancer	3.64e-05	0.000264	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—hematologic cancer	3.61e-05	0.000262	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—hematologic cancer	3.61e-05	0.000262	CcSEcCtD
Vismodegib—Decreased appetite—Prednisone—hematologic cancer	3.6e-05	0.000262	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—hematologic cancer	3.6e-05	0.000261	CcSEcCtD
Vismodegib—Rash—Prednisolone—hematologic cancer	3.6e-05	0.000261	CcSEcCtD
Vismodegib—Dermatitis—Prednisolone—hematologic cancer	3.59e-05	0.000261	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.59e-05	0.000261	CcSEcCtD
Vismodegib—Fatigue—Prednisone—hematologic cancer	3.57e-05	0.000259	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—hematologic cancer	3.55e-05	0.000258	CcSEcCtD
Vismodegib—Constipation—Prednisone—hematologic cancer	3.54e-05	0.000257	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—hematologic cancer	3.53e-05	0.000257	CcSEcCtD
Vismodegib—Nausea—Etoposide—hematologic cancer	3.43e-05	0.000249	CcSEcCtD
Vismodegib—Asthenia—Betamethasone—hematologic cancer	3.41e-05	0.000248	CcSEcCtD
Vismodegib—Asthenia—Dexamethasone—hematologic cancer	3.41e-05	0.000248	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—hematologic cancer	3.4e-05	0.000247	CcSEcCtD
Vismodegib—Gastrointestinal pain—Prednisone—hematologic cancer	3.39e-05	0.000246	CcSEcCtD
Vismodegib—Nausea—Prednisolone—hematologic cancer	3.39e-05	0.000246	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—hematologic cancer	3.38e-05	0.000245	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—hematologic cancer	3.38e-05	0.000245	CcSEcCtD
Vismodegib—Pruritus—Dexamethasone—hematologic cancer	3.37e-05	0.000244	CcSEcCtD
Vismodegib—Pruritus—Betamethasone—hematologic cancer	3.37e-05	0.000244	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—hematologic cancer	3.36e-05	0.000244	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.36e-05	0.000244	CcSEcCtD
Vismodegib—Vomiting—Triamcinolone—hematologic cancer	3.33e-05	0.000242	CcSEcCtD
Vismodegib—Rash—Triamcinolone—hematologic cancer	3.31e-05	0.00024	CcSEcCtD
Vismodegib—Dermatitis—Triamcinolone—hematologic cancer	3.3e-05	0.00024	CcSEcCtD
Vismodegib—Abdominal pain—Prednisone—hematologic cancer	3.28e-05	0.000238	CcSEcCtD
Vismodegib—Diarrhoea—Dexamethasone—hematologic cancer	3.26e-05	0.000236	CcSEcCtD
Vismodegib—Diarrhoea—Betamethasone—hematologic cancer	3.26e-05	0.000236	CcSEcCtD
Vismodegib—Nervous system disorder—Epirubicin—hematologic cancer	3.18e-05	0.000231	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.15e-05	0.000229	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—hematologic cancer	3.15e-05	0.000229	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—hematologic cancer	3.13e-05	0.000227	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—hematologic cancer	3.13e-05	0.000227	CcSEcCtD
Vismodegib—Nausea—Triamcinolone—hematologic cancer	3.11e-05	0.000226	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.11e-05	0.000226	CcSEcCtD
Vismodegib—Dyspepsia—Methotrexate—hematologic cancer	3.05e-05	0.000221	CcSEcCtD
Vismodegib—Vomiting—Betamethasone—hematologic cancer	3.03e-05	0.00022	CcSEcCtD
Vismodegib—Vomiting—Dexamethasone—hematologic cancer	3.03e-05	0.00022	CcSEcCtD
Vismodegib—Decreased appetite—Methotrexate—hematologic cancer	3.01e-05	0.000219	CcSEcCtD
Vismodegib—Rash—Dexamethasone—hematologic cancer	3e-05	0.000218	CcSEcCtD
Vismodegib—Rash—Betamethasone—hematologic cancer	3e-05	0.000218	CcSEcCtD
Vismodegib—Dermatitis—Dexamethasone—hematologic cancer	3e-05	0.000218	CcSEcCtD
Vismodegib—Dermatitis—Betamethasone—hematologic cancer	3e-05	0.000218	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.99e-05	0.000217	CcSEcCtD
Vismodegib—Fatigue—Methotrexate—hematologic cancer	2.99e-05	0.000217	CcSEcCtD
Vismodegib—Asthenia—Prednisone—hematologic cancer	2.97e-05	0.000216	CcSEcCtD
Vismodegib—Pain—Methotrexate—hematologic cancer	2.96e-05	0.000215	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.95e-05	0.000214	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—hematologic cancer	2.94e-05	0.000214	CcSEcCtD
Vismodegib—Pruritus—Prednisone—hematologic cancer	2.93e-05	0.000213	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—hematologic cancer	2.91e-05	0.000211	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—hematologic cancer	2.85e-05	0.000207	CcSEcCtD
Vismodegib—Diarrhoea—Prednisone—hematologic cancer	2.84e-05	0.000206	CcSEcCtD
Vismodegib—Gastrointestinal pain—Methotrexate—hematologic cancer	2.83e-05	0.000206	CcSEcCtD
Vismodegib—Nausea—Betamethasone—hematologic cancer	2.83e-05	0.000205	CcSEcCtD
Vismodegib—Nausea—Dexamethasone—hematologic cancer	2.83e-05	0.000205	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—hematologic cancer	2.82e-05	0.000205	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.8e-05	0.000203	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—hematologic cancer	2.79e-05	0.000203	CcSEcCtD
Vismodegib—Pain—Epirubicin—hematologic cancer	2.77e-05	0.000201	CcSEcCtD
Vismodegib—Constipation—Epirubicin—hematologic cancer	2.77e-05	0.000201	CcSEcCtD
Vismodegib—Abdominal pain—Methotrexate—hematologic cancer	2.74e-05	0.000199	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.73e-05	0.000198	CcSEcCtD
Vismodegib—Gastrointestinal pain—Epirubicin—hematologic cancer	2.65e-05	0.000192	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—hematologic cancer	2.64e-05	0.000192	CcSEcCtD
Vismodegib—Vomiting—Prednisone—hematologic cancer	2.63e-05	0.000191	CcSEcCtD
Vismodegib—Rash—Prednisone—hematologic cancer	2.61e-05	0.00019	CcSEcCtD
Vismodegib—Dermatitis—Prednisone—hematologic cancer	2.61e-05	0.00019	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—hematologic cancer	2.61e-05	0.000189	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.59e-05	0.000188	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—hematologic cancer	2.59e-05	0.000188	CcSEcCtD
Vismodegib—Pain—Doxorubicin—hematologic cancer	2.56e-05	0.000186	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—hematologic cancer	2.56e-05	0.000186	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—hematologic cancer	2.56e-05	0.000186	CcSEcCtD
Vismodegib—Asthenia—Methotrexate—hematologic cancer	2.48e-05	0.00018	CcSEcCtD
Vismodegib—Nausea—Prednisone—hematologic cancer	2.46e-05	0.000179	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.45e-05	0.000178	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—hematologic cancer	2.45e-05	0.000178	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—hematologic cancer	2.37e-05	0.000172	CcSEcCtD
Vismodegib—Diarrhoea—Methotrexate—hematologic cancer	2.37e-05	0.000172	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—hematologic cancer	2.33e-05	0.000169	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—hematologic cancer	2.29e-05	0.000166	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—hematologic cancer	2.22e-05	0.000161	CcSEcCtD
Vismodegib—Vomiting—Methotrexate—hematologic cancer	2.2e-05	0.00016	CcSEcCtD
Vismodegib—Rash—Methotrexate—hematologic cancer	2.18e-05	0.000159	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—hematologic cancer	2.18e-05	0.000158	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—hematologic cancer	2.15e-05	0.000156	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—hematologic cancer	2.12e-05	0.000154	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—hematologic cancer	2.06e-05	0.00015	CcSEcCtD
Vismodegib—Nausea—Methotrexate—hematologic cancer	2.06e-05	0.000149	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—hematologic cancer	2.05e-05	0.000149	CcSEcCtD
Vismodegib—Rash—Epirubicin—hematologic cancer	2.04e-05	0.000148	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—hematologic cancer	2.04e-05	0.000148	CcSEcCtD
Vismodegib—Nausea—Epirubicin—hematologic cancer	1.92e-05	0.00014	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—hematologic cancer	1.91e-05	0.000138	CcSEcCtD
Vismodegib—Rash—Doxorubicin—hematologic cancer	1.89e-05	0.000137	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—hematologic cancer	1.89e-05	0.000137	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—hematologic cancer	1.78e-05	0.000129	CcSEcCtD
Vismodegib—ABCB1—Metabolism—CRABP1—hematologic cancer	3.95e-06	4.33e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC22A1—hematologic cancer	3.95e-06	4.33e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SPHK1—hematologic cancer	3.95e-06	4.33e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—NCOR1—hematologic cancer	3.95e-06	4.33e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GSTM1—hematologic cancer	3.95e-06	4.33e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ALOX5—hematologic cancer	3.95e-06	4.32e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ENO2—hematologic cancer	3.94e-06	4.32e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—AKT1—hematologic cancer	3.93e-06	4.31e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CD—hematologic cancer	3.92e-06	4.3e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ALOX5—hematologic cancer	3.85e-06	4.22e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	3.85e-06	4.22e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTT1—hematologic cancer	3.85e-06	4.21e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTT1—hematologic cancer	3.82e-06	4.19e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NUP98—hematologic cancer	3.82e-06	4.19e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—UGT1A1—hematologic cancer	3.8e-06	4.16e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.79e-06	4.15e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTAP—hematologic cancer	3.78e-06	4.14e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.77e-06	4.13e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SDC1—hematologic cancer	3.76e-06	4.12e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SDC1—hematologic cancer	3.74e-06	4.1e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NUP98—hematologic cancer	3.73e-06	4.09e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—AKT1—hematologic cancer	3.73e-06	4.08e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ADCY7—hematologic cancer	3.71e-06	4.07e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NCOA3—hematologic cancer	3.71e-06	4.07e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3R1—hematologic cancer	3.7e-06	4.06e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC22A1—hematologic cancer	3.69e-06	4.05e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CRABP1—hematologic cancer	3.69e-06	4.05e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NUP214—hematologic cancer	3.68e-06	4.04e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.65e-06	3.99e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NCOA3—hematologic cancer	3.62e-06	3.97e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ADCY7—hematologic cancer	3.62e-06	3.97e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ABCG2—hematologic cancer	3.61e-06	3.95e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MTR—hematologic cancer	3.61e-06	3.95e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—JAK2—hematologic cancer	3.6e-06	3.94e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ALOX5—hematologic cancer	3.6e-06	3.94e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NUP214—hematologic cancer	3.6e-06	3.94e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.59e-06	3.93e-05	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.58e-06	3.92e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.57e-06	3.91e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.55e-06	3.88e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ENO2—hematologic cancer	3.54e-06	3.88e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MTR—hematologic cancer	3.52e-06	3.86e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ABCG2—hematologic cancer	3.52e-06	3.86e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—MTHFR—hematologic cancer	3.49e-06	3.82e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NUP98—hematologic cancer	3.49e-06	3.82e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ENO2—hematologic cancer	3.46e-06	3.79e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTT1—hematologic cancer	3.43e-06	3.76e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CB—hematologic cancer	3.42e-06	3.75e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.39e-06	3.72e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ADCY7—hematologic cancer	3.38e-06	3.71e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NCOA3—hematologic cancer	3.38e-06	3.71e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.38e-06	3.7e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.37e-06	3.69e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—FHL2—hematologic cancer	3.37e-06	3.69e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NUP214—hematologic cancer	3.36e-06	3.68e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SDC1—hematologic cancer	3.36e-06	3.68e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTT1—hematologic cancer	3.35e-06	3.67e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.32e-06	3.64e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AGRN—hematologic cancer	3.3e-06	3.62e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	3.3e-06	3.62e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MTR—hematologic cancer	3.29e-06	3.61e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ABCG2—hematologic cancer	3.29e-06	3.61e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SDC1—hematologic cancer	3.28e-06	3.59e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	3.25e-06	3.56e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ENO2—hematologic cancer	3.23e-06	3.54e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.21e-06	3.51e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NQO1—hematologic cancer	3.2e-06	3.5e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CD44—hematologic cancer	3.2e-06	3.5e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NQO1—hematologic cancer	3.18e-06	3.48e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CD44—hematologic cancer	3.18e-06	3.48e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.16e-06	3.47e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IL2—hematologic cancer	3.14e-06	3.44e-05	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.14e-06	3.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—IDH2—hematologic cancer	3.13e-06	3.43e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HMMR—hematologic cancer	3.13e-06	3.43e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.13e-06	3.43e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.13e-06	3.43e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.11e-06	3.41e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.08e-06	3.38e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SDC1—hematologic cancer	3.06e-06	3.35e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.03e-06	3.32e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYCS—hematologic cancer	3.02e-06	3.31e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYCS—hematologic cancer	3.01e-06	3.3e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	3.01e-06	3.29e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—HSP90AA1—hematologic cancer	2.99e-06	3.27e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ARNTL—hematologic cancer	2.94e-06	3.23e-05	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	2.94e-06	3.22e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CG—hematologic cancer	2.93e-06	3.21e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.92e-06	3.2e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.89e-06	3.16e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CA9—hematologic cancer	2.86e-06	3.14e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ACP5—hematologic cancer	2.86e-06	3.14e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CD44—hematologic cancer	2.85e-06	3.13e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NQO1—hematologic cancer	2.85e-06	3.13e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOR2—hematologic cancer	2.83e-06	3.1e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—EP300—hematologic cancer	2.82e-06	3.09e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.79e-06	3.06e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NQO1—hematologic cancer	2.79e-06	3.05e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CD44—hematologic cancer	2.79e-06	3.05e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.76e-06	3.02e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SRC—hematologic cancer	2.74e-06	3e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CREBBP—hematologic cancer	2.72e-06	2.98e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.7e-06	2.96e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYCS—hematologic cancer	2.7e-06	2.96e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—IDH1—hematologic cancer	2.69e-06	2.95e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.69e-06	2.95e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	2.68e-06	2.94e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—hematologic cancer	2.67e-06	2.92e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTP1—hematologic cancer	2.67e-06	2.92e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TXN—hematologic cancer	2.66e-06	2.92e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.66e-06	2.92e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.66e-06	2.92e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTP1—hematologic cancer	2.65e-06	2.9e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—hematologic cancer	2.64e-06	2.89e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYCS—hematologic cancer	2.64e-06	2.89e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—HSP90AA1—hematologic cancer	2.62e-06	2.87e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.61e-06	2.85e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CD44—hematologic cancer	2.6e-06	2.85e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NQO1—hematologic cancer	2.6e-06	2.85e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.58e-06	2.83e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CD—hematologic cancer	2.58e-06	2.82e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.56e-06	2.81e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.55e-06	2.79e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ALB—hematologic cancer	2.54e-06	2.79e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MAPK3—hematologic cancer	2.52e-06	2.77e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ABCB1—hematologic cancer	2.52e-06	2.77e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ABCB1—hematologic cancer	2.51e-06	2.75e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.5e-06	2.74e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYCS—hematologic cancer	2.46e-06	2.7e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NCOR1—hematologic cancer	2.45e-06	2.68e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTM1—hematologic cancer	2.45e-06	2.68e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TGFB1—hematologic cancer	2.45e-06	2.68e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	2.45e-06	2.68e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NCOR1—hematologic cancer	2.44e-06	2.67e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTM1—hematologic cancer	2.44e-06	2.67e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.44e-06	2.67e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.44e-06	2.67e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3R1—hematologic cancer	2.43e-06	2.67e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.41e-06	2.65e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.38e-06	2.61e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.37e-06	2.6e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTP1—hematologic cancer	2.32e-06	2.54e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.3e-06	2.52e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NUP98—hematologic cancer	2.3e-06	2.52e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—hematologic cancer	2.27e-06	2.49e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.25e-06	2.47e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CB—hematologic cancer	2.25e-06	2.46e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.23e-06	2.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.23e-06	2.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NUP214—hematologic cancer	2.22e-06	2.43e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.2e-06	2.41e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.19e-06	2.4e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.19e-06	2.4e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTR—hematologic cancer	2.17e-06	2.38e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.17e-06	2.38e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.17e-06	2.38e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—MTHFR—hematologic cancer	2.17e-06	2.37e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—MTHFR—hematologic cancer	2.15e-06	2.36e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NCOR1—hematologic cancer	2.13e-06	2.34e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTM1—hematologic cancer	2.13e-06	2.34e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ENO2—hematologic cancer	2.13e-06	2.33e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.1e-06	2.3e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CA—hematologic cancer	2.08e-06	2.28e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.06e-06	2.26e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.05e-06	2.25e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SDC1—hematologic cancer	2.02e-06	2.21e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—hematologic cancer	2.02e-06	2.21e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.99e-06	2.18e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.99e-06	2.18e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—hematologic cancer	1.94e-06	2.13e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.93e-06	2.12e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—hematologic cancer	1.93e-06	2.11e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.91e-06	2.09e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.9e-06	2.08e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MTHFR—hematologic cancer	1.89e-06	2.07e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—EP300—hematologic cancer	1.85e-06	2.03e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.82e-06	1.99e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CG—hematologic cancer	1.81e-06	1.98e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.76e-06	1.93e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.72e-06	1.88e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CD44—hematologic cancer	1.72e-06	1.88e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.7e-06	1.87e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—hematologic cancer	1.7e-06	1.87e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.69e-06	1.85e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CREBBP—hematologic cancer	1.68e-06	1.84e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.62e-06	1.78e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYCS—hematologic cancer	1.62e-06	1.78e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.61e-06	1.77e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.6e-06	1.75e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CD—hematologic cancer	1.59e-06	1.74e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.58e-06	1.74e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ALB—hematologic cancer	1.58e-06	1.73e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.55e-06	1.7e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.51e-06	1.65e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.51e-06	1.65e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3R1—hematologic cancer	1.5e-06	1.65e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.48e-06	1.62e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CREBBP—hematologic cancer	1.47e-06	1.61e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.43e-06	1.57e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.43e-06	1.56e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ALB—hematologic cancer	1.41e-06	1.54e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	1.39e-06	1.53e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.39e-06	1.53e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CB—hematologic cancer	1.39e-06	1.52e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ALB—hematologic cancer	1.38e-06	1.51e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.37e-06	1.5e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CA—hematologic cancer	1.37e-06	1.5e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.35e-06	1.48e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.35e-06	1.48e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.32e-06	1.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.32e-06	1.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.32e-06	1.44e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.3e-06	1.43e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ALB—hematologic cancer	1.28e-06	1.41e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.24e-06	1.36e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.23e-06	1.35e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.21e-06	1.33e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—hematologic cancer	1.2e-06	1.32e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—hematologic cancer	1.2e-06	1.31e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.16e-06	1.27e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—EP300—hematologic cancer	1.15e-06	1.26e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—EP300—hematologic cancer	1.14e-06	1.25e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.13e-06	1.24e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—hematologic cancer	1.12e-06	1.23e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—hematologic cancer	1.08e-06	1.18e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—hematologic cancer	1.05e-06	1.15e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—EP300—hematologic cancer	1.03e-06	1.12e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—EP300—hematologic cancer	1e-06	1.1e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—hematologic cancer	9.8e-07	1.07e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	9.77e-07	1.07e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—EP300—hematologic cancer	9.35e-07	1.02e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.05e-07	9.92e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.58e-07	9.41e-06	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	8.5e-07	9.31e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ALB—hematologic cancer	8.47e-07	9.28e-06	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CA—hematologic cancer	8.45e-07	9.26e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.11e-07	8.88e-06	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.59e-07	8.31e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.48e-07	8.2e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CA—hematologic cancer	7.4e-07	8.11e-06	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—hematologic cancer	6.94e-07	7.61e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	6.92e-07	7.58e-06	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—hematologic cancer	6.9e-07	7.56e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—hematologic cancer	6.47e-07	7.08e-06	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—hematologic cancer	6.2e-07	6.79e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—EP300—hematologic cancer	6.17e-07	6.76e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—hematologic cancer	6.05e-07	6.63e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—hematologic cancer	5.65e-07	6.19e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.56e-07	5e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—hematologic cancer	3.73e-07	4.08e-06	CbGpPWpGaD
